RFA for Flat Type High-grade and Medium-grade Intraepithelial Squamous Neoplasia
Multicenter, prospective cohort clinical trial in greater China
Esophageal Squamous Cell Neoplasia (ESCN)
DEVICE: Radiofrequency ablation
Percentage of Subjects With Complete Response (CR), The primary endpoint is the percentage of subjects with "complete response (CR)", defined as complete eradication of squamous histological abnormalities (MGIN or worse) within the treatment area (TA) at 12 months after the initial treatment session, 12 month
Complete Response at Three Months, Number of patients with a CR after primary RFA, defined as absence of MGIN or worse in any of the biopsies from the treatment area at the three months visit, 3 Months|Complete Response Within the Treatment Area, Number of patients demonstrating complete response within the treatment area (TA), defined as detection of ESCC in biopsy or resection specimen at any time within the first 12 months., 3, 6 and 12 Month|Disease Progression Outside the Treatment Area, Proportion of patients demonstrating MGIN or worse outside the TA during treatment phase or follow-up, Initial, 3, 6, 9 and 12 month
Multicenter, prospective cohort clinical trial in greater China